HRP20150900T1 - NOVI proNGF MUTANTI I NJIHOVA UPORABA ZA PROIZVODNJU BETA-NGF - Google Patents
NOVI proNGF MUTANTI I NJIHOVA UPORABA ZA PROIZVODNJU BETA-NGF Download PDFInfo
- Publication number
- HRP20150900T1 HRP20150900T1 HRP20150900TT HRP20150900T HRP20150900T1 HR P20150900 T1 HRP20150900 T1 HR P20150900T1 HR P20150900T T HRP20150900T T HR P20150900TT HR P20150900 T HRP20150900 T HR P20150900T HR P20150900 T1 HRP20150900 T1 HR P20150900T1
- Authority
- HR
- Croatia
- Prior art keywords
- prongf
- prongf mutant
- ngf
- mutant
- iii
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 239000000243 solution Substances 0.000 claims 7
- 230000008707 rearrangement Effects 0.000 claims 5
- VBAOEVKQBLGWTH-UHFFFAOYSA-N 2-pyridin-4-ylethanethiol Chemical compound SCCC1=CC=NC=C1 VBAOEVKQBLGWTH-UHFFFAOYSA-N 0.000 claims 4
- 229960003180 glutathione Drugs 0.000 claims 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 3
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 claims 3
- 101710129634 Beta-nerve growth factor Proteins 0.000 claims 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 claims 2
- 108010024636 Glutathione Proteins 0.000 claims 2
- 108010053070 Glutathione Disulfide Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- 102000004142 Trypsin Human genes 0.000 claims 2
- 108090000631 Trypsin Proteins 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims 2
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- 125000006247 phenyl propyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 238000004153 renaturation Methods 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- 239000012588 trypsin Substances 0.000 claims 2
- WOUANPHGFPAJCA-UHFFFAOYSA-N 2-[benzyl(methyl)amino]ethanol Chemical compound OCCN(C)CC1=CC=CC=C1 WOUANPHGFPAJCA-UHFFFAOYSA-N 0.000 claims 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 1
- 235000019393 L-cystine Nutrition 0.000 claims 1
- 239000004158 L-cystine Substances 0.000 claims 1
- 108010006519 Molecular Chaperones Proteins 0.000 claims 1
- 229920002684 Sepharose Polymers 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 230000003196 chaotropic effect Effects 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 229960003067 cystine Drugs 0.000 claims 1
- 238000004925 denaturation Methods 0.000 claims 1
- 230000036425 denaturation Effects 0.000 claims 1
- 229910052587 fluorapatite Inorganic materials 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 claims 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 1
- 210000003000 inclusion body Anatomy 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 claims 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (11)
1. proNGF mutant naznačen time da je mjesto cijepanja proteaze R1SK3R4 supstituirano na položajima R1 i K3 koji odgovaraju položajima 101 i 103 ljudskog divljeg tipa proNGF sekvence (SEQ ID NO: 1) s Valinom na položaju 101 i s Alaninom na položaju 103.
2. proNGF mutant prema zahtjevu 1, naznačen time da se mutant dobiva pomoću rekombinantne ekspresije u prokariotskim stanicama, poželjno pomoću rekombinantne ekspresije u E. coli.
3. Postupak za pripremu biološki aktivnog ljudskog beta-NGF naznačen time da sadrži
(i) osiguravanje proNGF mutanta prema zahtjevima 1 ili 2, te
(ii) cijepanje proNGF mutanta da se dobije aktivni ljudski beta-NGF.
4. Postupak prema zahtjevu 3 naznačen time da sadrži korake:
a. otapanje proNGF mutanta prema zahtjevima 1 ili 2 pomoću otapanja inkluzijskih tijela u otopini za denaturaciju;
b. prenošenje proNGF mutanta u otopinu za ponovno preslagivanje gdje denaturirani proNGF podrazumijeva biološki aktivnu konformaciju,
c. pročišćavanje ponovno presloženog proNGF mutanta,
d. cijepanje pro-sekvence proNGF mutanta da se dobije aktivni beta-NGF.
5. Postupak prema zahtjevu 4,
- naznačen time da otopina za denaturaciju sadrži otopinu koja sadrži (i) kaotropnu tvar, (ii) kelator, (iii) pufer, te (iv) redukcijsko sredstvo,
poželjno, pri čemu otopina za denaturaciju sadrži
i. 1 - 8 M Gvanidinij-HCl, poželjno 4-6 M,
ii. 0.01 - 1 M Tris,
iii. 1 - 50 mM EDTA,
iv. 1 - 100 mM odabranog od Glutationa (GSH) ili Cisteina,
v. pH 7.0 -10.0,
te poželjnije sadrži
i. 4 M Gvanidinij-HCl,
ii. 0.1 M Tris,
iii. 10 mM EDTA
iv. 5 mM GSH ili Cistein
v. pH 8.0, ili
- pri čemu otopina za ponovno preslagivanje sadrži
i. 0.5-1.0 M šaperona,
ii. 1- 10 mM metalnog kelatora,
iii. 0.1 -10 mM redoks sustava za preslagivanje,
iv. pH 8.0 - pH 11.0,
poželjno, pri čemu otopina za ponovno preslagivanje sadrži
i. 0.75 M Arginina,
ii. 5 mM EDTA
iii. 1 mM L-Cistina i 5 mM L-Cisteina, ili 1 mM GSSG (oksidiranog glutationa) i 5 mM GSH (reduciranog glutationa),
iv. pH 9.5.
6. Postupak prema zahtjevima 4 ili 5 naznačen time da se preslagivanje provodi kao impulsna renaturacija, poželjno, pri čemu u odnosu na konačni volumen ponovnog preslagivanja tijekom impulsne renaturacije, koncentracija Gvanidinij HCl ne prelazi 0.3 M i koncentracija proteina po impulsu ne smije prelaziti 50 µg/ml.
7. Postupak prema bilo kojem od zahtjeva 4-6, naznačen time da se proNGF mutant pročišćava pomoću kromatografije mješovitog tipa,
pri čemu je kolona za kromatografiju poželjno mješovita kolona sa sintetskim afinitetnim ligandom, poželjnije kolona sa 4-merkapto-etil-piridin (MEP), Heksilamino (HEA), fenilpropilamino (PPA), 2-merkapto-5-benzamidazol sulfo kiselinom (MBI), Kapto MMC (GEHC), N-benzil-N-metil etanolamin (GEHC), CHT hidroksapatit ili CHT fluoroapatit, najpoželjnije 4-merkapto-etil-piridin (MEP).
8. Postupak prema zahtjevima 4-7, naznačen time da se pro-oblik proNGF mutanta cijepa djelovanjem proteaze, poželjno djelovanjem serin proteaze, poželjnije djelovanjem tripsina.
9. Postupak prema zahtjevu 8, naznačen time da omjer tripsina prema proNGF mutantu je od 1 : 200 -1 : 100.000, poželjno od 1 : 5.000 - 1 : 20.000, te je poželjnije 1 : 10.000 (w/w).
10. Postupak prema zahtjevima 4 do 9 naznačen time da nadalje sadrži dodatni korak pročišćavanja beta-NGF, poželjno s kolonskom kromatografijom, poželjnije sa SP Sepharose HP kolonom.
11. Uporaba proNGF mutanta prema bilo kojem od zahtjeva 1 ili 2 naznačena time da je za proizvodnju ljudskog beta-NGF.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11194208 | 2011-12-19 | ||
PCT/EP2012/076251 WO2013092776A1 (en) | 2011-12-19 | 2012-12-19 | Novel prongf mutants and uses thereof in the production of beta-ngf |
EP12805695.9A EP2672984B1 (en) | 2011-12-19 | 2012-12-19 | Novel prongf mutants and uses thereof in the production of beta-ngf |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150900T1 true HRP20150900T1 (hr) | 2015-10-09 |
Family
ID=47428641
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150900TT HRP20150900T1 (hr) | 2011-12-19 | 2015-08-26 | NOVI proNGF MUTANTI I NJIHOVA UPORABA ZA PROIZVODNJU BETA-NGF |
HRP20180307TT HRP20180307T1 (hr) | 2011-12-19 | 2018-02-21 | Novi mutanti prongf-a i njihova upotreba u proizvodnji beta-ngf-a |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180307TT HRP20180307T1 (hr) | 2011-12-19 | 2018-02-21 | Novi mutanti prongf-a i njihova upotreba u proizvodnji beta-ngf-a |
Country Status (28)
Country | Link |
---|---|
US (3) | US9617322B2 (hr) |
EP (2) | EP2672984B1 (hr) |
JP (4) | JP6039146B2 (hr) |
KR (2) | KR20160120788A (hr) |
CN (2) | CN104203264B (hr) |
AU (1) | AU2012357052B2 (hr) |
BR (1) | BR112014014913B1 (hr) |
CA (1) | CA2859262C (hr) |
CY (2) | CY1117016T1 (hr) |
DK (2) | DK2672984T3 (hr) |
EA (1) | EA031333B1 (hr) |
ES (2) | ES2657344T3 (hr) |
HK (1) | HK1202055A1 (hr) |
HR (2) | HRP20150900T1 (hr) |
HU (2) | HUE036265T2 (hr) |
IL (1) | IL233137A0 (hr) |
LT (1) | LT2907521T (hr) |
MX (2) | MX353074B (hr) |
NO (1) | NO2907521T3 (hr) |
PL (2) | PL2672984T3 (hr) |
PT (2) | PT2672984E (hr) |
RS (2) | RS56893B1 (hr) |
SG (2) | SG11201402585PA (hr) |
SI (2) | SI2672984T1 (hr) |
SM (1) | SMT201500201B (hr) |
TR (1) | TR201802360T4 (hr) |
WO (1) | WO2013092776A1 (hr) |
ZA (1) | ZA201403753B (hr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2672984E (pt) | 2011-12-19 | 2015-10-01 | Wacker Chemie Ag | Novos mutantes de prongf e suas utilizações na produção de beta-ngf |
US20160220639A1 (en) * | 2013-09-11 | 2016-08-04 | New York University | Methods and compositions for treating bone diseases |
EP3406259A1 (en) | 2017-05-24 | 2018-11-28 | Dompé farmaceutici S.p.A. | Neurotrophins for use in the treatment of hearing loss |
CN108456681B (zh) * | 2018-03-26 | 2019-10-11 | 江苏中新医药有限公司 | 高效表达重组人神经生长因子的基因组合 |
WO2019207106A1 (en) | 2018-04-27 | 2019-10-31 | Chiesi Farmaceutici Spa | Production of nerve growth factor (ngf) and of muteins thereof |
AU2019293579A1 (en) * | 2018-06-29 | 2021-01-07 | The Doshisha | Formulation containing emricasan |
EP3852785A1 (en) | 2018-09-17 | 2021-07-28 | Chiesi Farmaceutici S.p.A. | Agent for treatment of dermatological disorders |
IT201900014646A1 (it) * | 2019-08-12 | 2021-02-12 | Consiglio Nazionale Ricerche | Peptide neurotrofico resistente alle proteasi per il trattamento terapeutico di patologie neurodegenerative e/o cutanee |
MX2022002833A (es) * | 2019-09-17 | 2022-04-06 | Chiesi Farm Spa | Agente para usarse en el tratamiento o prevencion de trastornos oftalmicos. |
IL302317A (en) | 2020-10-28 | 2023-06-01 | Dompe Farm Spa | Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them |
EP4039269A1 (en) | 2021-02-05 | 2022-08-10 | Dompe' Farmaceutici S.P.A. | Ngf isoform for use in the treatment of ocular pathologies |
WO2022221351A1 (en) | 2021-04-13 | 2022-10-20 | Dompé Farmaceutici S.P.A. | Treatment of neuropathic corneal pain with ngf |
EP4311554A1 (en) | 2022-07-29 | 2024-01-31 | Dompé farmaceutici S.p.a. | Combination for use in ophthalmology |
EP4316505A1 (en) | 2022-08-05 | 2024-02-07 | Dompé farmaceutici S.p.a. | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
EP4342485A1 (en) | 2022-09-23 | 2024-03-27 | Dompe' Farmaceutici S.P.A. | Ngf for the treatment of spasticity |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4139000A1 (de) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf |
ATE257514T1 (de) | 1998-10-09 | 2004-01-15 | Scil Proteins Gmbh | Verfahren zur gewinnung von aktivem beta-ngf |
US20030040082A1 (en) | 2001-02-16 | 2003-02-27 | Mark Tuszynski | Mutant pro-neurotrophin with improved activity |
EP1575477B1 (en) | 2001-05-25 | 2012-04-25 | Cornell Research Foundation, Inc. | HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR |
DE10360483B4 (de) | 2003-12-22 | 2007-11-15 | Scil Proteins Gmbh | Expressionsvektor und dessen Verwendung |
WO2005068498A2 (en) | 2004-01-19 | 2005-07-28 | Nsgene A/S | Human therapeutic cells secreting nerve growth factor |
US20080050776A1 (en) | 2006-05-26 | 2008-02-28 | Kenneth Neet | Stable mutated pro nerve growth factors |
CN101260398B (zh) | 2007-03-07 | 2013-06-05 | 舒泰神(北京)生物制药股份有限公司 | 神经生长因子基因定位改造动物及其制备方法和应用 |
PT2672984E (pt) | 2011-12-19 | 2015-10-01 | Wacker Chemie Ag | Novos mutantes de prongf e suas utilizações na produção de beta-ngf |
-
2012
- 2012-12-19 PT PT128056959T patent/PT2672984E/pt unknown
- 2012-12-19 EP EP12805695.9A patent/EP2672984B1/en active Active
- 2012-12-19 HU HUE15157320A patent/HUE036265T2/hu unknown
- 2012-12-19 AU AU2012357052A patent/AU2012357052B2/en active Active
- 2012-12-19 CN CN201280062855.6A patent/CN104203264B/zh active Active
- 2012-12-19 KR KR1020167027254A patent/KR20160120788A/ko not_active Application Discontinuation
- 2012-12-19 JP JP2014546588A patent/JP6039146B2/ja active Active
- 2012-12-19 DK DK12805695.9T patent/DK2672984T3/en active
- 2012-12-19 ES ES15157320.1T patent/ES2657344T3/es active Active
- 2012-12-19 RS RS20180159A patent/RS56893B1/sr unknown
- 2012-12-19 PT PT151573201T patent/PT2907521T/pt unknown
- 2012-12-19 MX MX2014007317A patent/MX353074B/es active IP Right Grant
- 2012-12-19 US US14/366,460 patent/US9617322B2/en active Active
- 2012-12-19 SG SG11201402585PA patent/SG11201402585PA/en unknown
- 2012-12-19 TR TR2018/02360T patent/TR201802360T4/tr unknown
- 2012-12-19 KR KR1020147019162A patent/KR101837802B1/ko active IP Right Grant
- 2012-12-19 SI SI201230289T patent/SI2672984T1/sl unknown
- 2012-12-19 CA CA2859262A patent/CA2859262C/en active Active
- 2012-12-19 MX MX2017012894A patent/MX370861B/es unknown
- 2012-12-19 SG SG10201605028VA patent/SG10201605028VA/en unknown
- 2012-12-19 PL PL12805695T patent/PL2672984T3/pl unknown
- 2012-12-19 SI SI201231212T patent/SI2907521T1/en unknown
- 2012-12-19 BR BR112014014913-5A patent/BR112014014913B1/pt active IP Right Grant
- 2012-12-19 CN CN201711352074.1A patent/CN109400693A/zh active Pending
- 2012-12-19 PL PL15157320T patent/PL2907521T3/pl unknown
- 2012-12-19 WO PCT/EP2012/076251 patent/WO2013092776A1/en active Application Filing
- 2012-12-19 EA EA201491155A patent/EA031333B1/ru unknown
- 2012-12-19 ES ES12805695.9T patent/ES2545701T3/es active Active
- 2012-12-19 DK DK15157320.1T patent/DK2907521T3/en active
- 2012-12-19 RS RS20150561A patent/RS54220B1/en unknown
- 2012-12-19 NO NO15157320A patent/NO2907521T3/no unknown
- 2012-12-19 EP EP15157320.1A patent/EP2907521B1/en active Active
- 2012-12-19 HU HUE12805695A patent/HUE027245T2/en unknown
- 2012-12-19 LT LTEP15157320.1T patent/LT2907521T/lt unknown
-
2014
- 2014-05-22 ZA ZA2014/03753A patent/ZA201403753B/en unknown
- 2014-06-15 IL IL233137A patent/IL233137A0/en active IP Right Grant
-
2015
- 2015-03-12 HK HK15102539.7A patent/HK1202055A1/xx unknown
- 2015-08-20 SM SM201500201T patent/SMT201500201B/xx unknown
- 2015-08-26 CY CY20151100747T patent/CY1117016T1/el unknown
- 2015-08-26 HR HRP20150900TT patent/HRP20150900T1/hr unknown
- 2015-12-22 US US14/978,407 patent/US10308694B2/en active Active
-
2016
- 2016-11-03 JP JP2016215749A patent/JP6622683B2/ja active Active
-
2018
- 2018-02-21 HR HRP20180307TT patent/HRP20180307T1/hr unknown
- 2018-02-21 CY CY20181100195T patent/CY1119926T1/el unknown
- 2018-08-07 JP JP2018148261A patent/JP2019011330A/ja active Pending
- 2018-08-08 JP JP2018148957A patent/JP2019006781A/ja active Pending
-
2019
- 2019-04-05 US US16/376,969 patent/US20200031893A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150900T1 (hr) | NOVI proNGF MUTANTI I NJIHOVA UPORABA ZA PROIZVODNJU BETA-NGF | |
ES2219649T3 (es) | Repliegue de polipeptidos similares al factor de crecimiento similar a insulina recombinante (igf-i). | |
Deng et al. | Purification and characterization of a novel fibrinolytic enzyme from the polychaete, Neanthes japonica (Iznka) | |
Trexler et al. | Folding autonomy of the kringle 4 fragment of human plasminogen. | |
US20070009506A1 (en) | Methods for production of recombinant urokinase | |
US8187837B2 (en) | Optimized purification process of recombinant growth factor protein | |
Im et al. | Bypassing the kinetic trap of serpin protein folding by loop extension | |
ES2216181T3 (es) | Procedimiento para preparar dimero purificado de factor derivado de hueso. | |
Schmoldt et al. | A fusion protein system for the recombinant production of short disulfide bond rich cystine knot peptides using barnase as a purification handle | |
WO2011151714A1 (en) | Modified sak gene for the production of recombinant proteins | |
JP2006506332A (ja) | インターロイキン−4およびその突然変異蛋白質の精製法 | |
JP5485873B2 (ja) | ヒトフューリンのための予備的な精製方法 | |
Caglič et al. | Fungal β-trefoil trypsin inhibitors cnispin and cospin demonstrate the plasticity of the β-trefoil fold | |
US20210330762A1 (en) | Medical application of mutant plasminogen and plasmin polypeptide therapeutics | |
US20140051832A1 (en) | Method for the production of recombinant human factor viii | |
ES2280211T3 (es) | Metodo para eliminar residuos de alanina, situados en extremos terminales de n, a partir de polipeptidos, con una aminopeptidasa procedente de aeromonas. | |
RU2009107894A (ru) | Рекомбинантный интерферон-бета с повышенной биологической активностью | |
CA2552790C (en) | Process for the purification of bacterially expressed proteins | |
Wang et al. | High hydrostatic pressure refolding of highly hydrophobic protein: A case study of recombinant human interferon β-1b from inclusion bodies | |
CN106754842A (zh) | 一种胰蛋白酶制备方法 | |
RU2395582C2 (ru) | СПОСОБ РАСЩЕПЛЕНИЯ ПОЛИПЕПТИДОВ С ИСПОЛЬЗОВАНИЕМ ВАРИАНТА ПРОТЕАЗЫ ОmpТ | |
MX2012012212A (es) | Procedimiento para la preparacion de trombina recombinante. | |
Jianhui et al. | Solid-phase chemical synthesis and oxidative refolding of Hainantoxin-III | |
CHOREV et al. | Effects of hydrophobic substitutions at position 18 on the potency of parathyroid hormone antagonists | |
Aguda et al. | Production and purification of TAL6003: A novel version of the protease plasmin |